Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1449 of 5804
-
Could a TB drug make brain zaps work better for depression?
Symptom relief OngoingThe goal of this clinical trial is to investigate if the drug D-Cycloserine (DCS) improves the antidepressant effects of Intermittent Theta Burst Stimulation (iTBS), a non-invasive brain stimulation therapy, in patients with Major Depressive Disorder (MDD). The main questions it …
Phase: PHASE2 • Sponsor: The Alfred • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
Double-Drug attack on stubborn IBD shows promise
Disease control CompletedThe aim of this retrospective and prospective observational study is to investigate and compare the real-world effectiveness and safety of different dual-target combination therapies in patients with inflammatory bowel disease (IBD). The key questions to be addressed are: In pa…
Sponsor: Xijing Hospital of Digestive Diseases • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug duo takes on tough lymphoma
Disease control Recruiting nowThis study is researching an experimental drug called REGN5837 in combination with another drug, odronextamab (called "study drug\[s\]"), in patients with relapsed or refractory aggressive B-cell Non-Hodgkin Lymphomas (B-NHLs). The study has 2 parts. The aim of the first part (d…
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
AI reads chest X-Rays to predict lung cancer risk
Diagnosis OngoingArtificial intelligence (AI) based algorithms have demonstrated increased accuracy in predicting the risk of Lung Cancer among patients with an incidental pulmonary nodule (IPN) on chest radiographs. Qure.ai, an AI company specializing in the reading of chest X- Rays (CXRs) by a …
Sponsor: AstraZeneca • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
Phone app aims to curb diabetes in rural hispanic populations
Prevention CompletedThe goal of this Randomized Controlled Trial (RCT) is to test the effectiveness of a mobile, web-based diabetes prevention program for Hispanics living in rural communities. The main question it aims to answer is: Does STEPS, a mobile, web-based diabetes prevention program, reduc…
Phase: NA • Sponsor: ISA Associates, Inc. • Aim: Prevention
Last updated Jun 27, 2026 09:07 UTC
-
New vaccine combo aims to train immune system to fight bladder cancer
Disease control OngoingThis phase I trial tests the safety and side effects of a PD-L1/IDO peptide vaccine (IO102-IO103) in combination with pembrolizumab in treating patients with non-muscle invasive bladder cancer. IO102-IO103 is a novel IDO and PD-L1 peptide based immune-modulatory therapeutic. It i…
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Bacteria battle cancer: modified salmonella starves tumors in new trial
Disease control Recruiting nowObjectives: To characterize safety, tolerability, MTD and OBD of intratumoral injection of SGN1 in patients with advanced solid tumors, and to preliminarily investigate the efficacy and safety of SGN1 in specific tumor subtypes. Study Rationale: The mechanism of action for SGN1 …
Phase: PHASE1, PHASE2 • Sponsor: Guangzhou Sinogen Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug cocktail aims to outsmart Hard-to-Treat lymphoma
Disease control OngoingThis phase II trial tests the safety, side effects, and best dose of TTI-621 (closed to enrollment) or TTI-622 in combination with pembrolizumab in treating patients with diffuse large B-cell lymphoma that has come back after a period of improvement (relapsed) or that does not re…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Nerve block may stop Post-Surgery heart flutter
Prevention CompletedThe purpose of this study is to test if a nerve block procedure called a stellate ganglion block can help decrease the chance of atrial fibrillation after surgery. Atrial fibrillation is the abnormal, fast beating of the upper chambers of the heart. Stellate ganglion blockade has…
Phase: PHASE2, PHASE3 • Sponsor: Mayo Clinic • Aim: Prevention
Last updated Jul 12, 2026 00:00 UTC
-
New hope for advanced cancers: JANX008 enters human testing
Disease control OngoingThis study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or m…
Phase: PHASE1 • Sponsor: Janux Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Spit test could spot heart failure Flare-Ups
Diagnosis Recruiting nowThe purpose of this study is to determine the relationship between the levels of Ribonucleic acid (RNA) circulating molecules, including ones in extracellular vesicles from different organs in the blood and in the saliva of patients with Acute Decompensated Heart Failure (ADHF) a…
Sponsor: Massachusetts General Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 07:57 UTC
-
New cancer drug IDE161 enters human testing
Disease control OngoingThe purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Could a CF drug help people with a different lung disease?
Disease control CompletedStudy participants with non-cystic fibrosis bronchiectasis will be given Trikafta for four weeks. The researchers will monitor clinical endpoints, quality of life, and weight. Additionally, cutaneous punch biopsy material material or blood samples from participants who agree to d…
Phase: PHASE4 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Seated vibration boosts recovery in chronic stroke patients
Symptom relief CompletedA 4-week program of vibration training in a seated position combined with conventional rehabilitation led to significant improvements in unaffected side lower limb muscle strength, functional recovery, quality of life, and self-esteem in patients with chronic stroke. No significa…
Phase: NA • Sponsor: CHIA-HUEI LIN, PhD • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
Can two drugs beat opioid relapse? new trial aims to find out
Disease control Recruiting nowThis study will evaluate the effectiveness of a new pharmacological approach to increase efficacy of treatment with extended release naltrexone (XR-naltrexone) for individuals with opioid use disorder by combining it with buprenorphine-naloxone. This is a two arm, double-blind, p…
Phase: PHASE2, PHASE3 • Sponsor: New York State Psychiatric Institute • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Blood tests could reveal hidden clues in aggressive brain cancer
Knowledge-focused TerminatedThe purpose of this study is to better define longitudinal genomic alterations in patients with glioblastoma (GBM), and to determine if plasma circulating tumor DNA (ctDNA) or cell free DNA (cfDNA) is associated with disease recurrence, survival, tumor characteristics, and/or per…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
New drug combo aims to tame stubborn gout flares
Disease control CompletedD-0120 is being tested in combination with Allopurinol in adult subjects with Gout.
Phase: PHASE2 • Sponsor: InventisBio Co., Ltd • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New targeted cancer drug STX-478 enters human trials
Disease control Recruiting nowStudy STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate S…
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Real-World study tracks Epidyolex's Long-Term impact on seizures
Disease control OngoingThis is a multi-center, non-interventional and prospective study of patients receiving Epidyolex as part of standard clinical practice in France. The study will state an overview of patient characteristics and clinical history (including age, sex, diagnosis, duration of epilepsy,…
Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New program aims to prevent nurse suicide by pairing online screening with resilience training
Disease control CompletedThe overall purpose of this study is to evaluate the efficacy of an intervention designed to prevent nurse suicide. This randomized controlled trial will test the modified Interactive Screening Program (mISP) alone and the mISP combined with a program called MINDBODYSTRONG. The …
Phase: NA • Sponsor: Ohio State University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC